Overview

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.
Phase:
Phase 1
Details
Lead Sponsor:
The Medicines Company
Treatments:
Cangrelor
Moxifloxacin